AI Article Synopsis
- Sialadenitis, a common salivary gland condition, can be hard to diagnose, especially when symptoms are mild; biomarkers from medical imaging may provide more reliable diagnosis.
- The study involved 46 patients diagnosed with sialadenitis and 90 control subjects, analyzing fat fraction data from MRI scans using the IDEAL-IQ method and categorizing participants by body mass index (BMI).
- Results showed a significant difference in fat fraction between control (38.57%) and sialadenitis groups (23.69%), indicating the IDEAL-IQ marker is a valuable diagnostic tool, particularly beneficial for less experienced clinicians.
Article Abstract
Background: The diagnosis of sialadenitis, the most frequent disease of the salivary glands, is challenging when the symptoms are mild. In such cases, biomarkers can be used as definitive diagnostic indicators. Recently, biomarkers have been developed by extracting and analyzing pathological and morphological features from medical imaging. This study aimed to establish a diagnostic reference for sialadenitis based on the quantitative magnetic resonance imaging (MRI) biomarker IDEAL-IQ and assess its accuracy.
Methods: Patients with sialadenitis (n = 46) and control subjects (n = 90) that underwent MRI were selected. Considering that the IDEAL-IQ value is a sensitive fat fractional marker to the body mass index (BMI), all subjects were also categorized as under-, normal-, and overweight. The fat fraction of parotid gland in the control and sialadenitis groups were obtained using IDEAL-IQ map. The values from the subjects in the control and sialadenitis groups were compared in each BMI category. For comparison, t-tests and receiver operating characteristic (ROC) curve analyses were performed.
Results: The IDEAL-IQ fat faction of the control and sialadenitis glands were 38.57% and 23.69%, respectively, and the differences were significant. The values were significantly lower in the sialadenitis group (P), regardless of the BMI types. The area under the ROC curve (AUC) was 0.83 (cut-off value: 28.72) in patients with sialadenitis. The AUC for under-, normal-, and overweight individuals were 0.78, 0.81, and 0.92, respectively.
Conclusions: The fat fraction marker based on the IDEAL-IQ method was useful as an objective indicator for diagnosing sialadenitis. This marker would aid less-experienced clinicians in diagnosing sialadenitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236577 | PMC |
| http://dx.doi.org/10.1186/s12903-023-03024-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between Quantitative Magnetic Resonance Imaging Measures and Functional Changes in Patients With Duchenne Muscular Dystrophy.
Muscle Nerve
December 2024
AMRA Medical AB, Linköping, Sweden.
Introduction/aims: Improved methodologies to monitor the progression of Duchenne muscular dystrophy (DMD) are needed, especially in the context of clinical trials. We report changes in muscle magnetic resonance imaging (MRI) parameters in participants with DMD, including changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI) and their relationship to changes in functional parameters.
Methods: MRI data were obtained as part of a clinical study (NCT02310763) of domagrozumab, an antibody-targeting myostatin that negatively regulates skeletal muscle mass.
Detecting white adipose tissue browning in mice with in vivo R* mapping at 9.4T MRI.
J Lipid Res
December 2024
Department of Radiology, University of Illinois at Chicago, Chicago, IL, USA; Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL, USA.
White adipose tissue (WAT) browning is considered a promising strategy to combat obesity and related metabolic diseases. Currently, fat-water fraction (FWF) has been used as a marker for the loss of lipids associated with WAT browning. However, FWF may not be sensitive to metabolic changes and cannot specifically reflect iron-regulated metabolism during browning.
View Article and Find Full Text PDFSafety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study.
J Hepatol
December 2024
Phase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. Electronic address:
Background And Aims: Glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) are key regulators of glucose and lipid metabolism. In the present study, we assessed the safety and efficacy of a novel GLP-1/FGF21 dual agonist HEC88473 for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) combined with type 2 diabetes mellitus (T2DM).
Methods: This was a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase 1b/2a trial.
Accuracy of Controlled Attenuation Parameter for Liver Steatosis in High-Risk Patients for MASLD Using MRI-Proton Density Fat Fraction as Reference Standard.
Dig Dis Sci
December 2024
Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aim: Controlled attenuation parameter (CAP) enables the noninvasive diagnosis of liver steatosis. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) is increasingly used over biopsy for the assessment of steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease (MASLD). We assessed the accuracy of CAP for liver steatosis defined as MRI-PDFF ≥ 5%.
View Article and Find Full Text PDFEffects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.
Diabetol Metab Syndr
December 2024
Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Road, Shanghai, 200127, China.
Aims: To observe the effects of liraglutide on abdominal fat distribution in Chinese subjects with obesity in 12 weeks, and further to explore the correlation between abdominal fat content and glucose metabolism after monotherapy.
Methods: This study recruited 71 obese subjects. All the subjects have received liraglutide monotherapy (0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!